Tanezumab
Tanezumab
Tanezumab (pronounced ta-ne-zu-mab) is a monoclonal antibody designed for the treatment of pain. It is developed by Pfizer and Lilly.
Etymology
The name 'Tanezumab' is derived from the systematic naming of monoclonal antibodies. The '-mab' suffix indicates it is a monoclonal antibody, while 'tanezu' is a unique stem used for the naming of this particular drug.
Mechanism of Action
Tanezumab works by targeting and inhibiting nerve growth factor (NGF), a protein involved in the transmission of pain signals from peripheral tissues to the spinal cord and brain. By blocking NGF, Tanezumab can effectively reduce pain sensation.
Clinical Trials and Uses
Tanezumab has been studied in several clinical trials for conditions such as osteoarthritis, chronic low back pain, and cancer pain. It is not currently approved by the FDA, but it has shown promise in reducing pain in these conditions.
Side Effects
Potential side effects of Tanezumab include peripheral neuropathy, arthralgia, and paresthesia. More serious side effects may include osteoarthritis worsening and joint related adverse events.
Related Terms
- Monoclonal antibody
- Nerve growth factor
- Pain
- Osteoarthritis
- Chronic low back pain
- Cancer pain
- Peripheral neuropathy
- Arthralgia
- Paresthesia
External links
- Medical encyclopedia article on Tanezumab
- Wikipedia's article - Tanezumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski